Molecular diagnostics company Tm Bioscience (Toronto, Canada) has been acquired by Luminex (Austin, TX), best known for its xMAP testing platform. Under the terms of the agreement, valued at $37.9 million, each Tm Bioscience share will be exchanged for 0.06 shares of Luminex common stock. This represents a 41.5% premium for Tm shares based on the stock’s closing price on the day of the acquisition. The transaction is expected to close in the first quarter of this year.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

February 2007 - Table of Contents

DTTR February 2007 (full PDF issue)

Siemens, GE Build Diagnostic Powerhouses

FDA to Hold Meeting on IVDMIA Draft Guidance

Pfizer Buys Diagnostic Rights for Genizon’s Disease Markers

New ACOG Guidelines Urge Earlier Screening for Down Syndrome

FDA Approves Ortho-Clinical’s Chagas Disease Screening Test

Initiative Seeks Routine SCID Screening for Newborns

Genomic Health Gets United, Aetna Reimbursement for Oncotype DX

Pharmacogenomics: Are Labs Believing the Hype?

JAMA Study Links Expanded Medicare Reimbursement With Increased Colon Cancer Screening, Earlier Diagnosis

Epigenomics Chooses New CEO, Contracts With Centocor for Cancer Biomarkers

Luminex to Buy Tm Bioscience for $37.9M

BD Closes on $350m TriPath Acquisition

IVD Stocks Rose 20% in 2006 Led by Immucor, Cholestech, Digene

Molecular Diagnostics: The Conference